Key Points Net loss per share (GAAP) was $(0.30), reflecting a higher loss than prior year. Cash and cash equivalents (GAAP) were $26.8 million, with a pro forma total of about $39 million as of June ...

Discover how AVA brings scale and reproducibility to organ‑chip technology, enabling human‑relevant insights that accelerate ...

Key Points Revenue grew 23% year over year (GAAP) in Q2 2025, but missed analyst estimates by $4.1 million (GAAP). The telehealth segment achieved 30.0% revenue growth, with Adjusted EBITDA rising 560 ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Operating expenses during the second quarter of 2025 were $25.8 million, an increase of $5.1 million, or 25%, compared to $20.7 million in the second quarter of 2024, mainly attributable to inclusion ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Concluding triumphantly, Mexico City's Youth Summit fosters collaboration among global leaders for peace and a sustainable ...

This is part of a series of stories featuring master’s degree programs at the University of Chicago. For more than a century, ...

It’s back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states’ exemptions to vaccine mandates for school entry ...

Today's call is being broadcast live via webcast, which is available on the Investors section of Axogen's website. Following the end of the live call, a replay will be available in the Investors ...